Abstract

The present invention refers to an in vitro method for the prognosis of patients suffering from HER2+ breast cancer, for the prediction of response to anti-HER2 therapies and/or for predicting survival benefit from anti-HER2 therapies.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 35/00 - Antineoplastic agents
• C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes

Abstract

Described herein are methods, compositions, and systems useful for detecting transplant rejection and associated abnormal conditions in solid organ transplant recipients, such as pancreatic transplant recipients, pancreatic and kidney transplant recipients, and simultaneous pancreatic and kidney transplant recipients. Methods described herein may involve combined assessment of blood gene expression profiles from an assessment of particular, related mRNA transcript levels and donor-derived cell-free nucleic acids (dd-cfDNA) or each an independent assessment of the mRNA transcript level as well as an independent assessment of the dd-cfDNA. Genes that correlate with pancreatic transplant rejection in simultaneous pancreatic and kidney transplant recipients are also disclosed.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• C12Q 1/6851 - Quantitative amplification
• C12Q 1/6881 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes

Abstract

The present invention provides Interleukin-13 Receptor Subunit Alpha-2 (IL13Rα2) targeting moieties, and CAR comprising them, which may be transduced or transformed into T cells. The resultant CARTs are suitable for the treatment and prevention of IL13Rα2-positive cancers, such as glioblastoma or diffuse intrinsic pontine glioma.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61P 35/00 - Antineoplastic agents
• A61K 40/11 - T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cellsLymphokine-activated killer [LAK] cells

Abstract

The present invention provides a fusion protein suitable to reduce graft-versus-host and host-versus-graft reactions in allogenic transplants. Said fusion protein comprises an anti-CD3 targeting moiety and a human cytomegalovirus US6 protein.

IPC Classes  ?

• C07K 14/725 - T-cell receptors
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 51/10 - Antibodies or immunoglobulinsFragments thereof
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C12N 15/62 - DNA sequences coding for fusion proteins
• A61K 40/30 - Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
• A61K 40/31 - Chimeric antigen receptors [CAR]

Abstract

The present invention relates to T cells expressing bispecific antibodies for BCMA and CD3 and uses thereof in the treatment of cancer, in particular cancers which overexpress BCMA antigen.

IPC Classes  ?

• A61K 40/11 - T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cellsLymphokine-activated killer [LAK] cells
• A61K 40/33 - AntibodiesT-cell engagers
• A61K 40/42 - Cancer antigens
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 35/00 - Antineoplastic agents
• A61P 35/02 - Antineoplastic agents specific for leukemia

Abstract

It relates to statins or their pharmaceutically acceptable salts for use in the prevention and/or treatment of splanchnic vascular dysfunctions in a patient which is a mammal wherein the prevention and/or treatment comprises inhibiting and/or reverting endothelial-to-mesenchymal transition of endothelial cells.

IPC Classes  ?

• A61K 31/22 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
• A61K 31/366 - Lactones having six-membered rings, e.g. delta-lactones
• A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
• A61K 31/404 - Indoles, e.g. pindolol
• A61K 31/47 - QuinolinesIsoquinolines
• A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 7/02 - Antithrombotic agentsAnticoagulantsPlatelet aggregation inhibitors

Abstract

The present invention relates to a CD7 targeting moiety, wherein the CD7 targeting moiety is an antibody, F(ab')2, Fab, scFab or scFv. The present invention further provides CD7 retention domains, CARs, nucleic acid, cells, pharmaceutical compositions and kits comprising the CD7 targeting moiety. Lastly, methods of treatment of a CD7-positive cancer, preferably T-ALL are also provided.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61P 35/02 - Antineoplastic agents specific for leukemia
• A61K 40/11 - T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cellsLymphokine-activated killer [LAK] cells
• A61K 40/31 - Chimeric antigen receptors [CAR]
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 40/42 - Cancer antigens

Abstract

A method of predicting the risk of progression of a cancer of a subject is described. The method can be used to infer the historical growth dynamics of an individual's cancer using fluctuating methylation clocks (FMCs). In the case of, for example, chronic lymphocytic leukaemia (CLL) (at least), the inferred growth rate holds valuable prognostic information, enabling patient stratification beyond that of standard clinical practice.

IPC Classes  ?

• G16B 20/00 - ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
• G16B 5/20 - Probabilistic models
• G16B 40/30 - Unsupervised data analysis
• G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment

Abstract

The present disclosure relates to a computer implemented method, system, and computer program for in silico surgical planification of a left atrial appendage occlusion (LAAO), wherein the risk of developing a device-associated thrombosis prior to a LAAO surgical intervention is evaluated. The positioning of the 3D model of the left atrial appendage occluder is determined according to anatomical characteristics of the left atrium of the patient, a first compression value and a structural simulation that provides a second compression value. The method further computes a risk score for device-induced thrombosis by analysing computational fluid dynamics calculations in conjunction with patient's medical parameters. This risk assessment aids in optimizing the positioning of the LAAO device, potentially reducing the incidence of post-operation thrombosis.

IPC Classes  ?

• A61B 17/12 - Surgical instruments, devices or methods for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels or umbilical cord
• A61B 34/10 - Computer-aided planning, simulation or modelling of surgical operations
• A61B 17/00 - Surgical instruments, devices or methods

Abstract

It relates to Elvitegravir or a pharmaceutically acceptable salt thereof for use in the treatment of a bacterial infection caused by multidrug-resistant Gram-positive bacteria.

IPC Classes  ?

• A61K 31/47 - QuinolinesIsoquinolines
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 31/04 - Antibacterial agents

Abstract

The present invention provides methods for obtaining human induced pluripotent stem cells (hiPSC)-derived neuronal cells which are useful for the diagnosis of neurological disorders associated with the presence of neuronal antibodies. In particular, the invention provides a method for obtaining hiPSC-derived neuronal cells, wherein the method comprises culturing neuronal progenitor cells for at least three weeks in proneural medium in optimized conditions. The invention further covers the use of neuronal cells obtained by the method of the invention as a diagnostic test in neurological disorders associated with the presence of neuronal antibodies and kits comprising the same.

IPC Classes  ?

• C12N 5/0793 - Neurons

Abstract

An instrument for transorbital endoscopic surgery is proposed. The instrument comprises a handle; a support element, the handle being movably attached, at one end, to the support element; a first arm and a second arm, each one comprising a fixing portion, which connects the arm to the support element, and an anchoring portion, which is releasably attached to the fixing portion, one of the anchoring portions being configured to be anchored to a first fissure of the orbital cavity and the other one of the anchoring portions being configured to be anchored to a second fissure of the orbital cavity, each one of the anchoring portions comprising a given curvature; a mesh, arranged between and connected to each one of the anchoring portions to gather the periorbital when the anchoring portions are anchored to the first and seconds fissures; and sensors to detect an applied pressure applied to the first and second fissures.

IPC Classes  ?

• A61B 17/02 - Surgical instruments, devices or methods for holding wounds open, e.g. retractorsTractors
• A61B 17/00 - Surgical instruments, devices or methods
• A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges

Abstract

Non-invasive biomarkers for the diagnosis and prognosis of portal hypertension. Advantageously, the markers allow to appropriately differentiate between the non-clinical and clinically significant portal hypertension, thus being possible a more precise management of the therapeutic protocols.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals

Abstract

An antigen-binding domain, antibody or chimeric antigen receptor that binds to CD84.

IPC Classes  ?

• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 35/02 - Antineoplastic agents specific for leukemia
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• C07K 14/725 - T-cell receptors
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• C12N 15/86 - Viral vectors

Abstract

The present invention provides new therapeutic approaches for the treatment or prevention of FGFR4-expressing cancers, including those resistant to other therapies.

IPC Classes  ?

• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• A61P 35/00 - Antineoplastic agents
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 31/00 - Medicinal preparations containing organic active ingredients
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

A method for diagnosing a probability of a human patient with encephalopathy symptoms has or may develop a herpes simplex encephalitis (HSE) related symptom

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

The present invention refers to a method for generating a humanized animal model of a mental disorder. The model is generated by implanting neural precursors from the olfactory neuroepithelium of patients with said mental disorder in the brain of adult animals. The model can be used for the study of the disease, as well as for the identification and evaluation of the efficacy of potential treatments against the disease.

IPC Classes  ?

• A01K 67/0271 - Chimeric vertebrates, e.g. comprising exogenous cells
• C12N 5/079 - Neural cells
• A01K 67/027 - New or modified breeds of vertebrates

Abstract

The present invention refers to a CD19-specific chimeric antigen receptor (CAR) T-cell therapy and to its use for treating CD19+ malignancies.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 35/00 - Antineoplastic agents
• A61P 35/02 - Antineoplastic agents specific for leukemia

Abstract

The present invention relates to liposomes that encapsulate uric acid, methods for its preparation and uses of said liposomes.

IPC Classes  ?

• A61K 31/522 - Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
• A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

The present invention relates to gene therapy for the treatment of Glutaric Aciduria type I (GA-1), wherein the treatment comprises the administration of a nucleic acid comprising an expression cassette comprising the nucleotide sequence of a chimeric promoter and the nucleotide sequence encoding for the human glutaryl-CoA dehydrogenase enzyme (GCDH). Virions, cells and pharmaceutical composition comprising said nucleic acid are also provided.

IPC Classes  ?

• C12N 15/86 - Viral vectors
• C12N 15/87 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation

Abstract

The present invention refers to the medical field. Particularly, the present invention refers to autologous/allogeneic CAR (chimeric antigen receptor)-T/NK cells for use in the treatment of invasive fungal infections.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 47/42 - ProteinsPolypeptidesDegradation products thereofDerivatives thereof, e.g. albumin, gelatin or zein
• A61P 31/10 - Antimycotics
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• C07K 14/725 - T-cell receptors
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells

Abstract

A method involves detecting in a sample an autoantibody binding specifically to one or more from Gluk1, Gluk2, Gluk3, Gluk4 and Gluk5, preferably Gluk2. An autoantibody binds specifically to one or more from Gluk1, Gluk2, Gluk3, Gluk4 and Gluk5, preferably Gluk2. A diagnostically useful carrier with a solid phase with an immobilized polypeptide contains one or more from Gluk1, Gluk2, Gluk3, Gluk4 and Gluk5, preferably Gluk2 or a variant thereof. The autoantibody can be used for diagnosing a neurological autoimmune disease or a cancer.

IPC Classes  ?

• G01N 33/564 - ImmunoassayBiospecific binding assayMaterials therefor for pre-existing immune complex or autoimmune disease
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The present invention relates to a CD229 and a BCMA targeting moiety, wherein the CD229 targeting moiety is an antibody, F(ab')2, Fab, scFab or scFv. The present invention further provides CARs, nucleic acid, cells, pharmaceutical compositions and kits comprising the CD229 and BCMA targeting moiety. Methods of treatment of a CD229-positive cancer, preferably Multiple Myeloma, are also provided.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61P 35/00 - Antineoplastic agents
• C07K 14/725 - T-cell receptors
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

Described herein are methods, compositions, and systems useful for detecting transplant rejection and associated abnormal conditions in solid organ transplant recipients, such as pancreatic transplant recipients, pancreatic and kidney transplant recipients, and simultaneous pancreatic and kidney transplant recipients. Methods described herein may involve combined assessment of blood gene expression profiles from an assessment of particular, related mRNA transcript levels and donor-derived cell-free nucleic acids (dd-cfDNA) or each an independent assessment of the mRNA transcript level as well as an independent assessment of the dd-cfDNA. Genes that correlate with pancreatic transplant rejection in simultaneous pancreatic and kidney transplant recipients are also disclosed.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

The present invention refers to an in vitro method for the prognosis of patients suffering from HER2+ breast cancer and/or for the prediction of response to anti-HER2 therapies in patients suffering from HER2+ breast cancer.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• C12Q 1/6844 - Nucleic acid amplification reactions

Abstract

The invention relates to a two-phase method for screening for colorectal cancer (CRC) using fecal microbiome profiling. The method comprises determining in a fecal sample isolated from the subjects the levels of two or more bacterial taxa, classifying with a computer algorithm in a first phase CRC samples vs. non-CRC samples and classifying with a computer algorithm in a second phase the samples that are classified as being non-CRC in the first phase into clinically relevant (CR) samples and non-CR samples using two or more bacterial taxa that are differentially abundant in CR samples relative to non-CR samples. The invention also relates to a kit comprising reagents for conducting the method and a computer program.

IPC Classes  ?

• C12Q 1/6809 - Methods for determination or identification of nucleic acids involving differential detection
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria

Abstract

in vitro in vitro use of DNA copy number alterations (CNAs) for predicting the response of patients with HR+/HER2− breast cancer to a treatment comprising targeted therapy, such as CDK4/6 inhibitors, and/or endocrine therapy; for the prognosis of patients with HR+/HER2− breast cancer; for monitoring patients with HR+/HER2− breast cancer; or for classifying patients with HR+/HER2− breast cancer into responder or non-responder to a treatment comprising targeted therapy, such as CDK4/6 inhibitors, and/or endocrine therapy.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

An antigen-binding domain, antibody or chimeric antigen receptor that binds to CD84.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C07K 14/725 - T-cell receptors
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

Combination therapy methods, compositions and kits Invention relates to combinations comprising: a) a compound of formula (I) Combination therapy methods, compositions and kits Invention relates to combinations comprising: a) a compound of formula (I) Combination therapy methods, compositions and kits Invention relates to combinations comprising: a) a compound of formula (I) or a pharmaceutically or veterinary acceptable salt thereof, wherein: R1 R2 and R3 have particular meaning; and (b) one or more drugs selected from the group consisting of i) a compound of formula (IV), or a pharmaceutically or veterinary acceptable salt thereof, Combination therapy methods, compositions and kits Invention relates to combinations comprising: a) a compound of formula (I) or a pharmaceutically or veterinary acceptable salt thereof, wherein: R1 R2 and R3 have particular meaning; and (b) one or more drugs selected from the group consisting of i) a compound of formula (IV), or a pharmaceutically or veterinary acceptable salt thereof, Combination therapy methods, compositions and kits Invention relates to combinations comprising: a) a compound of formula (I) or a pharmaceutically or veterinary acceptable salt thereof, wherein: R1 R2 and R3 have particular meaning; and (b) one or more drugs selected from the group consisting of i) a compound of formula (IV), or a pharmaceutically or veterinary acceptable salt thereof, wherein R5 and R6 have particular meaning, ii) a sphingosine-1-phosphate receptor inhibitor (S1PR modulator), and iii) a Signal transducer and activator of transcription 3 (STAT3) inhibitor. Particular combinations and single pharmaceutical compositions and kits of parts are disclosed. These combinations, single pharmaceutical compositions and kits of parts are for use in the treatment and/or prevention of an inflammatory neurological disease or condition which can result in the destruction or degeneration of axons or myelin in a subject in need thereof

IPC Classes  ?

• A61K 38/06 - Tripeptides
• A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
• A61K 31/397 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
• A61K 31/4245 - Oxadiazoles
• A61K 31/426 - 1,3-Thiazoles
• A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
• A61K 31/44 - Non-condensed pyridinesHydrogenated derivatives thereof
• A61K 31/18 - Sulfonamides
• A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
• A61K 31/47 - QuinolinesIsoquinolines
• A61K 31/409 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
• A61K 38/53 - Ligases (6)
• A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
• A61K 31/4015 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
• A61K 31/225 - Polycarboxylic acids
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Goods & Services

Apparatus and instruments for recording, transmitting, reproducing and processing sound, images and data; recorded and downloadable media and computer software for data analysis and diagnostics; computers and computer peripheral devices; diving suits; divers' masks; ear plugs for divers; nose clips for divers and swimmers; gloves for divers; breathing apparatus for underwater swimming; fire-extinguishing apparatus; downloadable and recorded bioinformatics software for sequencing data analysis; downloadable software for performing remote diagnostics; downloadable software for performing diagnostics; downloadable maintenance software; downloadable predictive maintenance software Scientific and technological services and research and design in the field of diagnostic bioinformatics and diagnostic computational analysis relating thereto; industrial analysis; industrial research and industrial design services; quality control and authentication services; design and development of computer hardware and software; development and testing of computing methods, algorithms and computer software; research and development in the field of scientific diagnostic preparations; computer aided diagnostic testing services; design and development of medical diagnostic apparatus; maintenance of computer software; repair of software [maintenance, updating]; creation, maintenance and adaptation of software; installation and maintenance of database software; maintenance of software for communication systems; rental and maintenance of computer software; design, maintenance and updating of computer software; installation, maintenance, repair and servicing of computer software; development, updating and maintenance of software and database systems; consultancy and information services relating to the design, programming and maintenance of computer software; research and development of computer software; research relating to the development of computer programs and software Medical diagnostic services; medical testing for diagnostic or treatment purposes

Goods & Services

Scientific, research, navigation, surveying, photographic, cinematographic, audiovisual, optical, weighing, measuring, signalling, detecting, testing, inspecting, life-saving and teaching apparatus and instruments; apparatus and instruments for conducting, switching, transforming, accumulating, regulating or controlling the distribution or use of electricity; apparatus and instruments for recording, transmitting, reproducing or processing sound, images or data; recorded and downloadable media, computer software, blank digital or analogue recording and storage media; mechanisms for coin-operated apparatus; cash registers, calculating devices; computers and computer peripheral devices; diving suits, divers' masks, ear plugs for divers, nose clips for divers and swimmers, gloves for divers, breathing apparatus for underwater swimming; fire-extinguishing apparatus; bioinformatics software; Software for remote diagnostics; Software for diagnostics and troubleshooting; Maintenance software; Predictive maintenance software. Scientific and technological services and research and design relating thereto; industrial analysis, industrial research and industrial design services; quality control and authentication services; design and development of computer hardware and software; Development and testing of computing methods, algorithms and software; Research and development in the field of diagnostic preparations; Computer aided diagnostic testing services; Design and development of medical diagnostic apparatus; Computer software maintenance; Repair of software [maintenance, updating]; Creation, maintenance and adaptation of software; installation and maintenance of database software; Maintenance of software for communication systems; Rental and maintenance of computer software; Design, maintenance and up-dating of computer software; Installation, maintenance, repair and servicing of computer software; Development, updating and maintenance of software and database systems; Consultancy and information services relating to the design, programming and maintenance of computer software; Research and development of computer software; Research relating to the development of computer programs and software. Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, aquaculture, horticulture and forestry services; medical diagnostic services; medical testing for diagnostic or treatment purposes.

Abstract

A diagnostically useful carrier includes a means for specifically capturing an antibody to a polypeptide from the group including squid MLC1 or squid MLC2 or a variant thereof in a sample from a subject. A method includes the step detecting in a sample from a subject the presence or absence of an antibody to squid MLC1 or squid MLC2. The polypeptide or the carrier or a polypeptide binding specifically to an IgE antibody from the sample of a patient to squid MLC1 or squid MLC2 are useful for the manufacture of a diagnostic kit, preferably for the diagnosis of allergy.

IPC Classes  ?

• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
• G01N 33/564 - ImmunoassayBiospecific binding assayMaterials therefor for pre-existing immune complex or autoimmune disease
• C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals
• A61K 38/00 - Medicinal preparations containing peptides

Abstract

The present invention relates to a device for transport and preservation of an ex vivo biological sample and corresponding method. The device comprises a chamber for containing the biological sample, delimitated by walls made of a thermal insulating material. The device, furthermore, incorporates cooling means that keep the temperature inside the chamber below the temperature outside the device. Finally, an ultrasound system suitable for generating and applying ultrasound on the biological sample is provided. The invention also proposes a method for transport and preservation which combines applying cooling and ultrasound to reduce cell damage in the biological sample.

IPC Classes  ?

• A01N 1/02 - Preservation of living parts
• A61N 7/00 - Ultrasound therapy

Abstract

The present invention concerns subject matter connected to or making use of IgLON5, IgLON5 fragments and variants of IgLON5 and IgLON5-fragments. In particular the present invention relates to a use of a polypeptide comprising one or more sequences of IgLON5, an IgLON5-fragment or a variant thereof for the diagnosis of a disease, in vitro methods for diagnosing such a disease, a polypeptide comprising one or more sequences of IgLON5, an IgLON5-fragment or a variant thereof or a nucleic acid encoding said polypeptide for use in the treatment of a disease, a pharmaceutical composition comprising such polypeptide, a method for treating such a disease, an autoantibody binding to IgLON5, an IgLON5-fragment or a variant thereof, a method for isolating such autoantibody, a medical or diagnostic device comprising such autoantibody or such polypeptide and a test kit for the diagnosis of a disease, which test kit comprises such autoantibody and/or such polypeptide.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• G01N 33/564 - ImmunoassayBiospecific binding assayMaterials therefor for pre-existing immune complex or autoimmune disease
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

The present invention provides a use of a GABA(A)R, GABA(A)R fragment, or homolog thereof or a cell expressing the GABA(A)R, GABA(A)R fragment, or homolog thereof for the prognosis, diagnosis or treatment of an autoimmune disease in a subject, methods of prognosticating, diagnosing or treating an autoimmune disease, an autoantibody binding to a GABA(A)R, GABA(A)R fragment, or homolog thereof, a method for isolating an antibody binding to a GABA(A)R, GABA(A)R fragment, or homolog thereof, and a test kit, pharmaceutical composition and medical or diagnostic device comprising a GABA(A)R, GABA(A)R fragment, or homolog thereof.

IPC Classes  ?

• A61K 38/00 - Medicinal preparations containing peptides
• G01N 33/564 - ImmunoassayBiospecific binding assayMaterials therefor for pre-existing immune complex or autoimmune disease
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• G01N 33/94 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving narcotics

Abstract

The present invention relates to a polypeptide or protein for use in a method of diagnosis or treatment of an autoimmune disease in a subject, characterized in that said polypeptide or protein comprises one or more epitopes derived from the protein DPPX. Further, the invention relates to a nucleic acid or vector encoding such polypeptide, to a cell comprising such a vector, to an in vitro diagnostic method and test kit involving such polypeptide, to a pharmaceutical composition comprising such polypeptide, to a medical device coated with such polypeptide or pharmaceutical composition and to methods for treating an autoimmune disease in a subject.

IPC Classes  ?

• G01N 33/564 - ImmunoassayBiospecific binding assayMaterials therefor for pre-existing immune complex or autoimmune disease
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• C12N 9/48 - Hydrolases (3.) acting on peptide bonds, e.g. thromboplastin, leucine aminopeptidase (3.4)
• A61L 31/10 - Macromolecular materials
• A61M 1/36 - Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation
• A61K 38/00 - Medicinal preparations containing peptides